FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 71.00% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-03-29
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 74.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-09-30 was 141.00%, a 6.62% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-09-30 was 151.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-03-31 was 389.00%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 71.00%, a 41.80% decline from fiscal 2021.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 122.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | 71.00% 10-K · filed 2023-03-29 | |||||
| 2022-03-31 | 74.00% 10-Q · filed 2022-05-12 | |||||
| 2021-12-31 | 122.00% 10-K · filed 2023-03-29 | |||||
| 2021-09-30 | 122.00% 10-Q · filed 2021-11-10 | |||||
| 2021-06-30 | 122.00% 10-Q · filed 2021-08-10 | |||||
| 2020-09-30 | 141.00% 10-Q · filed 2020-11-16 | |||||
| 2019-09-30 | 151.00% 10-Q · filed 2020-11-16 | |||||
| 2019-02-01 | 179.00% 10-Q · filed 2019-11-12 | 179.00% 10-Q · filed 2020-11-16 | ||||
| 2018-03-31 | 389.00% 10-Q · filed 2018-05-14 | |||||
| 2017-09-30 | 162.00% 10-Q · filed 2018-11-13 | |||||
| 2016-09-30 | 136.00% 10-Q · filed 2017-11-13 | |||||
| 2016-06-30 | 137.00% 10-Q · filed 2017-08-14 | |||||
| 2015-09-30 | 139.00% 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | 139.00% 10-Q · filed 2016-08-12 | |||||
| 2015-03-31 | 127.00% 10-Q · filed 2016-05-12 | |||||
| 2014-12-31 | 125.00% 10-Q · filed 2016-05-12 | |||||
| 2014-03-31 | 137.00% 10-Q · filed 2014-05-15 | |||||
| 2013-09-30 | 163.00% 10-Q · filed 2013-11-18 | |||||
| 2012-09-30 | 118.00% 10-Q · filed 2013-11-18 | |||||
| 2011-09-30 | 132.00% 10-Q · filed 2012-11-14 | |||||
| 2011-06-30 | 134.70% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |